Improving treatments for Alzheimer's disease using SHIP1 inhibitors
Optimization of SHIP1 Inhibitors for the Treatment of Alzheimer's Disease
This study is looking at new ways to help the brain clear out harmful substances linked to Alzheimer's disease by using special inhibitors that boost the brain's immune cells, which could lead to better treatments for patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-10941338 on NIH RePORTER |
What this research studies
This research focuses on developing and optimizing SHIP1 inhibitors to enhance the brain's ability to clear harmful beta-amyloid plaques associated with Alzheimer's disease. By targeting microglial cells, which are crucial for maintaining brain health and clearing neurotoxins, the study aims to improve the immune response in the brain. The approach involves understanding the genetic factors that influence microglial activity and how SHIP1 inhibitors can enhance this process. Patients may benefit from new therapeutic options that could slow down or prevent cognitive decline.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at high risk of developing the condition.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease, potentially improving cognitive function and quality of life for patients.
How similar studies have performed: Previous research has shown promising results in targeting microglial activity for Alzheimer's treatment, suggesting that this approach could be effective.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Richardson, Timothy I — Indiana University Indianapolis
- Study coordinator: Richardson, Timothy I
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.